Korea FDA OKs Samsung's Clinical Trial Application For Roche's MabThera Biosimilar
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea FDA approved March 8 Samsung Electronics' investigational new drug application to commence Phase I clinical trials of a biosimilar of Roche's MabThera, marking the first step of the electronics and semiconductor giant's ambition to enter the healthcare sector
You may also be interested in...
Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now
SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets
Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now
SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets
Celltrion Pushes Back Launch Of Roche And Johnson & Johnson Biosimilars To 2012
SEOUL - South Korea's biosimilar front-runner Celltrion said it will push back the anticipated launch of biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to early 2012, instead of the original plan for a launch in the second half of 2011